1. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group;Adès;Haematologica,2018
2. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells;Chen;Blood,1997
3. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells;Chen;Cancer Res.,2003
4. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment;Chen;Anal. Bioanal. Chem.,2013
5. Arsenic speciation in the blood of arsenite-treated F344 rats;Chen;Chem. Res. Toxicol.,2013